Cassava Sciences, Inc. (SAVA)
After hours:
| Previous close | 12.75 |
| Open | 13.00 |
| Bid | 14.89 x 200 |
| Ask | 14.95 x 700 |
| Day's range | 12.86 - 14.94 |
| 52-week range | 8.79 - 32.10 |
| Volume | |
| Avg. volume | 2,074,254 |
| Market cap | 715.805M |
| Beta (5Y monthly) | -0.57 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.17 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 13 Dec 2012 |
| 1y target est | 103.00 |
ZacksBiotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates
Cassava Sciences, Inc. (SAVA) and Lexeo Therapeutics (LXEO) are in the spotlight following updates.
GlobeNewswireCassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives
Rick Barry appointed Executive Chairman of the BoardRemi Barbier resigns as President and CEO and from the Board of DirectorsCassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Board of Directors has appointed Richard (Rick) Barry as Executive Chairman of the Board and as the Company’s principal executive officer, effective immediately. The Company is undertaking a search for a new permanent CEO. M
- Yahoo Finance Video
Cassava forms committee after US probe, researcher fraud
Cassava Sciences (SAVA) is reportedly forming a committee to investigate two senior employees. This comes after a US probe into fraud and a Cassava researcher was indicted by a jury over alleged fabrication of Alzheimer's drug trial results. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Luke Carberry Mogan.
